Efraim Duzman MD Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$156,105	45
2024	Research	$90,084	48
2023	Research	$221,511	28
2022	Research	$333,757	29
2021	Research	$503,313	39
2020	Research	$318,452	34
2019	Research	$269,699	23

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $1,262,851 111 payments
AbbVie, Inc. $630,070 135 payments

Studies the money was for Research payments · program years 2019–2025

A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $560,458 25 payments
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $372,129 23 payments
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $260,925 54 payments
A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $193,838 17 payments
Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension $172,075 19 payments
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $145,080 46 payments
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $41,026 6 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $38,452 15 payments
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $23,730 3 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $23,723 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.